Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

RC48-ADC demonstrated a promising efficacy with a manageable safety profile in patients with HER2⁺ locally advanced or mUC who had failed at least one line of systemic chemotherapy.